Complications of chemotherapy, a basic science update

Presse Medicale

Volumn 42, Issue 9 PART2, 2013, Pages

  Mazevet, Marianne ^a   Moulin, Maryline ^a   Llach Martinez, Anna ^a   Chargari, Cyrus ^b   Deutsch, Éric ^b   Gomez, Ana Maria ^a   Morel, Éric ^a  

^a Universite Paris Sud   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; BIOENERGY; CARDIOTOXICITY; CLINICAL RESEARCH; HEART MUSCLE CELL; HEART PROTECTION; HEMATOLOGIC MALIGNANCY; HUMAN; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; OXIDATIVE STRESS; SHORT SURVEY; SOFT TISSUE SARCOMA; SOLID TUMOR;

EID: 84884204152     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.06.011     Document Type: Short Survey

References (126)

1. Schimmel K.J., Richel D.J., van den Brink R.B., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004, 30:181-191.
2. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
3. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992, 19:670-686.
4. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009, 53(24):2231-2247.
5. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26(22):3777-3784.
6. Minow R.A., Benjamin R.S., Lee E.T., Gottlieb J.A. Adriamycin cardiomyopathy risk factors. Cancer 1977, 39(4):1397-1402.
7. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000, 207(1-2):77-86.
8. Ewer M.S., Yeh E.T.H. Cancer and the Heart 2013, People's Medical Publishing House, Ltd, USA, 2 Edition, January 1. Second Edition.
9. Zhang Y.W., Shi J., Li Y.J., Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp 2009, 57:435-445.
10. Menna P., Paz O.G., Chello M., Covino E., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012, 11(Suppl.1):S21-S36.
11. Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 2012, 52:1213-1225.
12. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61:154-171.
13. Salzer W.L., Devidas M., Carroll W.L., Winick N., Pullen J., Hunger S.P., et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia 2010, 24:355-370.
14. Tebbi C.K., London W.B., Friedman D., Villaluna D., De Alarcon P.A., Constine L.S., et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007, 25:493-500.
15. Sardao V.A., Oliveira P.J., Holy J., Oliveira C.R., Wallace K.B. Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 2009, 64:811-827.
16. Zhang C., Feng Y., Qu S., Wei X., Zhu H., Luo Q., et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 2011, 90:38-545.
17. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007, 67:8839-8846.
18. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
19. Dimitrakis P., Romay-Ogando M.I., Timolati F., Suter T.M., Zuppinger C. Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes. Cell Tissue Res 2012, 350:361-372.
20. Kawaguchi T., Takemura G., Kanamori H., Takeyama T., Watanabe T., Morishita K., et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res 2012, 96:456-465.
21. Sishi B.J., Loos B., van Rooyen J., Engelbrecht A.M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 2012, 85:124-134.
22. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006, 41:389-405.
23. Wallace K.B. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 2007, 7:101-107.
24. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009, 81:412-419.
25. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
26. Ventura-Clapier R., Garnier A., Veksler V., Joubert F. Bioenergetics of the failing heart. Biochim Biophys Acta 2011, 1813:1360-1372.
27. Carvalho R.A., Sousa R.P., Cadete V.J., Lopaschuk G.D., Palmeira C.M., Bjork J.A., et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 2010, 270:92-98.
28. Jirkovsky E., Popelova O., Krivakova-Stankova P., Vavrova A., Hroch M., Haskova P., et al. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on Nrf2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther 2012, 343:468-478.
29. Tokarska-Schlattner M., Dolder M., Gerber I., Speer O., Wallimann T., Schlattner U. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. Biochim Biophys Acta 2007, 1767:1276-1284.
30. Kuznetsov A.V., Margreiter R., Amberger A., Saks V., Grimm M. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta 2011, 1813:1144-1152.
31. Lebrecht D., Kirschner J., Geist A., Haberstroh J., Walker U.A. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. Cardiovasc Pathol 2010, 19:e167-e174.
32. Brenner C., Moulin M. Physiological roles of the permeability transition pore. Circ Res 2012, 111:1237-1247.
33. Montaigne D., Marechal X., Preau S., Baccouch R., Modine T., Fayad G., et al. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 2011, 11:22-26.
34. Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan Y. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 2010, 298:E751-E760.
35. Ventura-Clapier R., Garnier A., Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008, 79:208-217.
36. Wang S., Song P., Zou M.H. Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem 2012, 287:8001-8012.
37. Tokarska-Schlattner M., Zaugg M., da Silva R., Lucchinetti E., Schaub M.C., Wallimann T., et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 2005, 289:H37-H47.
38. Gratia S., Kay L., Potenza L., Seffouh A., Novel-Chate V., Schnebelen C., et al. Inhibition of AMPK signaling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res 2012, 95:290-299.
39. Danz E.D., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009, 46:1589-1597.
40. Konishi M., Haraguchi G., Ohigashi H., Ishihara T., Saito K., Nakano Y., et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 2010, 89:309-319.
41. Rowan R.A., Masek M.A., Billingham M.E. Ultrastructural morphometric analysis of endomyocardial biopsies. Idiopathic dilated cardiomyopathy, anthracycline cardiotoxicity, and normal myocardium. Am J Cardiovasc Pathol 1988, 2(2):137-144.
42. Zhang Y., Zhang T., Cao C.M., Xiao R.P. mTOR: good, bad, or ugly?. Cardiovasc Res 2012, 95(3):261-262.
43. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003, 93:105-115.
44. Minotti G., Ronchi R., Salvatorelli E., Menna P., Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 2001, 61(23):8422-8428.
45. Neilan T.G., Blake S.L., Ichinose F., Raher M.J., Buys E.S., Jassal D.S., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
46. Lebrecht D., Walker U.A. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):108-113.
47. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49:330-352.
48. Niu J., Azfer A., Wang K., Wang X., Kolattukudy P.E. Cardiac-targeted expression of soluble fas attenuates doxorubicin-induced cardiotoxicity in mice. J Pharmacol Exp Ther 2009, 328(3):740-748.
49. Kalivendi S.V., Konorev E.A., Cunningham S., Vanamala S.K., Kaji E.H., Joseph J., et al. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 2005, 389:527-539.
50. Ito T., Fujio Y., Takahashi K., Azuma J. Degradation of NFAT5, a transcriptional regulator of osmotic stress-related genes, is a critical event for doxorubicin-induced cytotoxicity in cardiac myocytes. J Biol Chem 2007, 282(2):1152-1160.
51. Kim D.S., Woo E.R., Chae S.W., Ha K.C., Lee G.H., Hong S.T., et al. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci 2007, 80(4):314-323.
52. Li H., Gu H., Sun B. Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 2007, 114(2):159-165.
53. Safa M., Zand H., Mousavizadeh K., Kazemi A., Bakhshayesh M., Hayat P. Elevation of cyclic AMP causes an imbalance between NF-kappaB and p53 in NALM-6 cells treated by doxorubicin. FEBS Lett 2010, 584(15):3492-3498.
54. Nitobe J., Yamaguchi S., Okuyama M., Nozaki N., Sata M., Miyamoto T., et al. Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res 2003, 57(1):119-128.
55. Nozaki N., Shishido T., Takeishi Y., Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004, 110(18):2869-2874.
56. Deniaud A., Sharaf el dein O., Maillier E., Poncet D., Kroemer G., Lemaire C., et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 2008, 27(3):285-299.
57. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006, 291(3):H1273-H1280.
58. Liu J., Mao W., Ding B., Liang C.S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 2008, 295:H1956-H1965.
59. Shizukuda Y., Matoba S., Mian O.Y., Nguyen T., Hwang P.M. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 2005, 273:25-32.
60. Zhu W., Soonpaa M.H., Chen H., Shen W., Payne R.M., Liechty E.A., et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009, 119(1):99-106.
61. Feridooni T., Hotchkiss A., Remley-Carr S., Saga Y., Pasumarthi K.B. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One 2011, 6(7):e22801.
62. Nithipongvanitch R., Ittarat W., Velez J.M., Zhao R., St Clair D.K., Oberley T.D. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment. J Histochem Cytochem 2007, 55:629-639.
63. Shacka J.J., Sahawneh M.A., Gonzalez J.D., Ye Y.Z., D'Alessandro T.L., Estévez A.G. Two distinct signaling pathways regulate peroxynitrite-induced apoptosis in PC12 cells. Cell Death Differ 2006, 13(9):1506-1514.
64. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 2004, 101(18):6975-6980.
65. Suliman H.B., Carraway M.S., Ali A.S., Reynolds C.M., Welty-Wolf K.E., Piantadosi C.A. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 2007, 117(12):3730-3741.
66. Park A.M., Nagase H., Liu L., Vinod Kumar S., Szwergold N., Wong C.M., et al. Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart. Cardiovasc Res 2011, 90(1):97-104.
67. Kawamura T., Hasegawa K., Morimoto T., Iwai-Kanai E., Miyamoto S., Kawase Y., et al. Expression of p300 protects cardiac myocytes from apoptosis in vivo. Biochem Biophys Res Commun 2004, 315(3):733-738.
68. Poizat C., Puri P.L., Bai Y., Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol 2005, 25(7):2673-2687.
69. Mercier I., Vuolo M., Madan R., Xue X., Levalley A.J., Ashton A.W., et al. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ 2005, 12(6):682-686.
70. An J., Li P., Li J., Dietz R., Donath S. ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J Mol Med (Berl) 2009, 87(4):401-410.
71. Fan G.C., Zhou X., Wang X., Song G., Qian J., Nicolaou P., et al. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. Circ Res 2008, 103(11):1270-1279.
72. Piantadosi C.A., Carraway M.S., Babiker A., Suliman H.B. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res 2008, 103(11):1232-1240.
73. Sawyer D.B., Peng X., Chen B., Pentassuglia L., Lim C.C. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?. Prog Cardiovasc Dis 2010, 53(2):105-113.
74. Thandavarayan R.A., Watanabe K., Sari F.R., Ma M., Lakshmanan A.P., Giridharan V.V., et al. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice. Free Radic Biol Med 2010, 49(9):1422-1431.
75. Shi J., Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp 2007, 55:61-75.
76. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007, 117(9):2431-2444.
77. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005, 434(7033):652-658.
78. Riad A., Bien S., Westermann D., Becher P.M., Loya K., Landmesser U., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695-699.
79. Casey T.M., Arthur P.G., Bogoyevitch M.A. Necrotic death without mitochondrial dysfunction-delayed death of cardiac myocytes following oxidative stress. Biochim Biophys Acta 2007, 1773:342-351.
80. Lim C.C., Zuppinger C., Guo X., Kuster G.M., Helmes M., Eppenberger H.M., et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004, 279:8290-8299.
81. Arbustini E., Brega A., Narula J. Ultrastructural definition of apoptosis in heart failure. Heart Fail Rev 2008, 13(2):121-135.
82. L'Ecuyer T., Allebban Z., Thomas R., Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol 2004, 286(6):H2057-H2064.
83. Ranek M.J., Wang X. Activation of the ubiquitin proteasome system in doxorubicin cardiomyopathy. Curr Hypertens Rep 2009, 11(6):389-395.
84. De Meyer G.R., Martinet W. Autophagy in the cardiovascular system. Biochim Biophys Acta 2009, 1793(9):1485-1495.
85. Lu L., Wu W., Yan J., Li X., Yu H., Yu X. Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 2009, 134(1):82-90.
86. Levine B., Sinha S., Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2001, 4:600-606.
87. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8(9):741-752.
88. Muñoz-Gámez J.A., Rodríguez-Vargas J.M., Quiles-Pérez R., Aguilar-Quesada R., Martín-Oliva D., de Murcia G., et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 2009, 5(1):61-74.
89. Smuder A.J., Kavazis A.N., Min K., Powers S.K. Doxorubicin-induced markers of myocardial autophagic signaling in sedentary and exercise trained animals. J Appl Physiol 2013, 115(2):176-185.
90. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
91. De Keulenaer G.W., Doggen K., Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010, 106:35-46.
92. Horie T., Ono K., Nishi H., Nagao K., Kinoshita M., Watanabe S., et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010, 87(4):656-664.
93. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Ann Rev Physiol 2008, 70:23-49.
94. Halperin E.C., Perez C.A., Brady L.W. Principles and practice of radiation oncology 2004, 2368. Lippincott Williams and Wilkins, a Wolters Kluwer business, Philadelphia, USA. 5th ed.
95. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71:310-321.
96. 2+ leak in chronic heart failure. Circ Res 2008, 103:1466-1472.
97. Saeki K., Obi I., Ogiku N., Shigekawa M., Imagawa T., Matsumoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 2002, 70:2377-2389.
98. Park I.Y., Kim E.J., Park H., Fields K., Dunker A.K., Kang C. Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Molecular Pharmacol 2005, 67:97-104.
99. Charlier H.A., Olson R.D., Thornock C.M., Mercer W.K., Olson D.R., Broyles T.S. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol 2005, 67:1505-1512.
100. Hanna A.D., Janczura M., Cho E., Dulhunty A.F., Beard N.A. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol 2011, 80:538-549.
101. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 2006, 38:535-545.
102. 2+ signaling at the dyads. Cardiovasc Res 2013, 98(2):248-258.
103. Wang G.X., Wang Y.X., Zhou X.B., Korth M. Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur J Pharmacol 2001, 423:99-107.
104. Wold L.E., Aberle N.S., Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev 2005, 29:294-299.
105. Sag C.M., Kohler A.C., Anderson M.E., Backs J., Maier L.S. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol 2011, 51:749-759.
106. Olson R.D., Mushlin P.S., Brenner D.E., Fleischer S., Cusack B.J., Chang B.K., et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 1988, 85:3585-3589.
107. Vile G., Winterbourn C. Thiol oxidation and inhibition of Ca-ATPase by adriamycin in rabbit heart microsomes. Biochem Pharmacol 1990, 39:769-774.
108. 2+-ATPase. Biochem Biophys Res Commun 2003, 303:504-507.
109. 2+-handling mechanisms in the sarcoplasmic reticulum in the rat. Canadian journal of physiology and pharmacology 2000, 78:329-338.
110. Gambliel H.A., Burke B.E., Cusack B.J., Walsh G.M., Zhang Y.L., Mushlin P.S., et al. Doxorubicin C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 2002, 291:433-438.
111. Quốc Lu'o'ng K.V., Nguyễn L.T. The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res 2012, 4:431-445.
112. Kenk M., Thackeray J.T., Thorn S.L., Dhami K., Chow B.J., Ascah K.J., et al. Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010, 17(2):254-263.
113. Kizaki K., Akatsuka K., Momozaki M., Fujimori Y., Uchide T., Temma K., et al. Changes in myocardial beta1-adrenergic receptor and stimulatory G-protein gene expression after chronic treatment with doxorubicin in rat. J Vet Med Sci 2004, 66(8):989-992.
114. Nagami K., Yoshikawa T., Suzuki M., Wainai Y., Anzai T., Handa S. Abnormal beta-adrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy. Jpn Circ J 1997, 61(3):249-255.
115. Koka S., Das A., Zhu S.G., Durrant D., Xi L., Kukreja R.C. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010, 334(3):1023-1030.
116. Bernstein D., Fajardo G., Zhao M., Urashima T., Powers J., Berry G., et al. Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 2005, 289(6):H2441-H2449.
117. Yoshida M., Shiojima I., Ikeda H., Komuro I. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 2009, 47(5):698-705.
118. Huelsenbeck J., Henninger C., Schad A., Lackner K.J., Kaina B., Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011, 11(2):e190.
119. Huelsenbeck S.C., Schorr A., Roos W.P., Huelsenbeck J., Henninger C., Kaina B., et al. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem 2012, 287(46):38590-38599.
120. Grünwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62(21):6141-6145.
121. Wang N., Guan P., Zhang J.P., Chang Y.Z., Gu L.J., Hao F.K., et al. Preventive effects of fasudil on adriamycin-induced cardiomyopathy: possible involvement of inhibition of RhoA/ROCK pathway. Food Chem Toxicol 2011, 49(11):2975-2982.
122. Doublier S., Riganti C., Voena C., Costamagna C., Aldieri E., Pescarmona G., et al. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol Cancer Res 2008, 6(10):1607-1620.
123. Machado V., Cabral A., Monteiro P., Gonçalves L., Providência L.A. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol 2008, 27(10):1277-1296.
124. Potiron V.A., Abderrhamani R., Giang E., Chiavassa S., Di Tomaso E., Maira S.M., et al. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions. Radiother Oncol 2013, 106(1):138-146.
125. Hwang S.Y., Jung J.W., Jeong J.S., Kim Y.J., Oh E.S., Kim T.H., et al. Dominant-negative Rac increases both inherent and ionizing radiation-induced cell migration in C6 rat glioma cells. Int J Cancer 2006, 118(8):2056-2063.
126. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13(1):1-10.